Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Vicente Alberola CandelSpanish Society of Medical Oncology

Abstract

Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.

References

Jun 14, 1990·The New England Journal of Medicine·H LudwigU Barnas
May 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S CascinuG Catalano
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R Abels
May 19, 1993·Journal of the National Cancer Institute·D C CaseC R Nichols
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GlaspyS Vadhan-Raj
Jun 15, 1999·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·M HenkeH Frommhold
Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Mar 14, 2000·Medical Oncology·M OzgurogluB Berkarda
May 1, 2001·British Journal of Haematology·F DammaccoS Rödjer
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LittlewoodUNKNOWN Epoetin Alfa Study Group
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GabriloveL H Einhorn
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I QuirtUNKNOWN Canadian Eprex Oncology Study Group
Jun 21, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·David CellaKelly Dineen
Jun 26, 2002·Seminars in Oncology·Timothy Littlewood, Franco Mandelli
Aug 22, 2002·Journal of the National Cancer Institute·Johan VansteenkisteUNKNOWN Aranesp 980297 Study Group
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Clinical Oncology. American Society of Hematology
Oct 3, 2002·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin alfa 990114 Study Group
Dec 20, 2002·The Oncologist·Louis B HarrisonDaniel Shasha
Apr 3, 2003·British Journal of Cancer·M BoogaertsUNKNOWN Epoetin beta QOL Working Group
Jul 25, 2003·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin Alfa 20000161 Study Group
Sep 6, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D KotasekUNKNOWN Aranesp 980291 Study Group
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael AuerbachJeevindra Rana
Sep 21, 2004·Cancer·Horng-Shiuann Wu, Maryellen McSweeney
Sep 29, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigRoscoe F Morton
Sep 29, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jose ChangCatherine Y Lau
Sep 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Heinz LudwigDirk Schrijvers

❮ Previous
Next ❯

Citations

Dec 25, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J L SteegmannM Pérez
May 6, 2020·European Heart Journal Supplements : Journal of the European Society of Cardiology·Andrés J Muñoz MartínJosé Manuel Soria Fernández

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.